Johnson & Johnson (NYSE:JNJ) Stock Position Decreased by Geneos Wealth Management Inc.

Posted by Defense World Staff on Jul 18th, 2023

Geneos Wealth Management Inc. lessened its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 8.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,903 shares of the company’s stock after selling 3,077 shares during the period. Geneos Wealth Management Inc.’s holdings in Johnson & Johnson were worth $5,255,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Veracity Capital LLC boosted its position in shares of Johnson & Johnson by 1.2% in the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after buying an additional 59 shares during the period. LCM Capital Management Inc boosted its position in Johnson & Johnson by 0.7% during the fourth quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after purchasing an additional 61 shares during the last quarter. Arbor Investment Advisors LLC boosted its position in Johnson & Johnson by 2.3% during the fourth quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after purchasing an additional 61 shares during the last quarter. Sierra Capital LLC boosted its position in Johnson & Johnson by 0.6% during the fourth quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock valued at $1,773,000 after purchasing an additional 61 shares during the last quarter. Finally, Retirement Planning Group boosted its position in Johnson & Johnson by 1.8% during the fourth quarter. Retirement Planning Group now owns 3,437 shares of the company’s stock valued at $607,000 after purchasing an additional 62 shares during the last quarter. Institutional investors and hedge funds own 67.57% of the company’s stock.

Johnson & Johnson Stock Down 0.5 %

Shares of JNJ stock opened at $159.06 on Tuesday. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. The firm has a market cap of $413.35 billion, a PE ratio of 33.28, a price-to-earnings-growth ratio of 2.73 and a beta of 0.55. The stock has a 50 day moving average of $160.13 and a 200-day moving average of $161.64.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating the consensus estimate of $2.51 by $0.17. The firm had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.67 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.65 EPS for the current year.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research reports. Raymond James reduced their price objective on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. UBS Group began coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price objective for the company. Atlantic Securities cut their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday, April 19th. Finally, Morgan Stanley upped their price target on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 19th. Seven research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $169.77.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.20% of the company’s stock.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Johnson & Johnson (NYSE:JNJ) Stock Position Decreased by Geneos Wealth Management Inc.

Johnson & Johnson Stock Down 0.5 %

Wall Street Analysts Forecast Growth

Insiders Place Their Bets

Johnson & Johnson Company Profile

Further Reading

You might be interested in: